Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires 199,072 Shares of Stock

OPKO Health, Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 199,072 shares of the company’s stock in a transaction on Friday, November 29th. The stock was purchased at an average cost of $1.53 per share, for a total transaction of $304,580.16. Following the purchase, the chief executive officer now directly owns 211,911,477 shares in the company, valued at approximately $324,224,559.81. This trade represents a 0.09 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Phillip Md Et Al Frost also recently made the following trade(s):

• On Friday, November 22nd, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The stock was purchased at an average cost of $1.59 per share, for a total transaction of $159,000.00.
• On Thursday, November 14th, Phillip Md Et Al Frost bought 100,000 shares of OPKO Health stock. The shares were acquired at an average price of $1.62 per share, with a total value of $162,000.00.
• On Friday, November 8th, Phillip Md Et Al Frost purchased 280,183 shares of OPKO Health stock. The stock was bought at an average price of $1.50 per share, with a total value of $420,274.50.

OPKO Health Trading Down 2.5 %

Shares of OPKO Health stock opened at $1.54 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.97 and a quick ratio of 2.69. The business has a fifty day simple moving average of $1.52 and a two-hundred day simple moving average of $1.45. OPKO Health, Inc. has a 1 year low of $0.85 and a 1 year high of $1.75. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -8.11 and a beta of 1.65.

Analysts Set New Price Targets

Several equities analysts recently weighed in on OPK shares. Piper Sandler reissued an “overweight” rating and issued a $3.00 target price on shares of OPKO Health in a research note on Tuesday, September 17th. Barrington Research reissued an “outperform” rating and issued a $2.25 price objective on shares of OPKO Health in a research report on Friday, November 8th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of OPKO Health in a report on Thursday, September 26th.

Institutional Trading of OPKO Health

Hedge funds have recently added to or reduced their stakes in the company. CIBC Asset Management Inc lifted its holdings in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 8,978 shares during the period. Hollencrest Capital Management increased its stake in shares of OPKO Health by 14.0% in the 2nd quarter. Hollencrest Capital Management now owns 90,000 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 11,020 shares during the last quarter. FMR LLC raised its holdings in shares of OPKO Health by 103.6% during the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of OPKO Health by 4.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 445,981 shares of the biotechnology company’s stock worth $536,000 after buying an additional 17,671 shares during the last quarter. Finally, Virtu Financial LLC acquired a new position in OPKO Health during the first quarter worth about $26,000. 64.63% of the stock is owned by institutional investors and hedge funds.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.